MMED Stock Analysis: MiniMed , Common Stock | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 4.222m USD | 12M Return: -17.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.4M
Rev. Trend: 99.5%
Warnings
Tailwinds
No distinct edge detected
Seasonality 0.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MiniMed Group, Inc. (NASDAQ: MMED) is a U.S.-based medical technology company that develops, manufactures, and markets equipment for diabetes management, operating as a subsidiary of Medtronic plc. Its product platform includes insulin pumps and pens, continuous glucose monitors (CGMs), consumables, and related software and services, serving insulin-dependent patients, which encompasses all individuals with Type 1 diabetes (T1D) and a subset of those with Type 2 diabetes (T2D). The company offers Automated Insulin Delivery (AID) systems that combine glucose sensing with automated insulin dosing, as well as Smart Multiple Daily Injection (MDI) solutions such as InPen, Simplera Sync, and the Guardian 4 sensor, supported by its CareLink software platform for patients, caregivers, and healthcare professionals. Founded in 1983 and headquartered in Northridge, California, MiniMed generated an IPO in March 2026 and currently has a market capitalization of approximately $4.4 billion, placing it in the mid-cap range.
Within the broader Healthcare sector and Medical Instruments & Supplies industry, the diabetes device market is typically characterized by a recurring-revenue business model, in which the sale of durable hardware (pumps, pens, sensors) is complemented by ongoing demand for disposable consumables such as infusion sets, reservoirs, and CGM sensors. Demand in this segment is structurally supported by the rising global prevalence of diabetes and the gradual shift toward connected, software-enabled therapy platforms that integrate hardware, data, and clinical support services.
- AID system adoption accelerates Diabetes segment revenue growth
- CGM competition intensifies from Dexcom and Abbott Libre
- Type 2 diabetes market expansion drives long-term volume growth
| Net Income: -521.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -3.34 > 1.0 |
| NWC/Revenue: 21.26% < 20% (prev 8.43%; Δ 12.83% < -1%) |
| CFO/TA 0.00 > 3% & CFO 3.00m > Net Income -521.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.92 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (256.6m) vs prev -8.62% < -2% |
| Gross Margin: 53.98% > 18% (prev 56.17%; Δ -2.19% > 0.5%) |
| Asset Turnover: 68.80% > 50% (prev 64.63%; Δ 4.18% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.14 (Total Current Assets 1.35b - Total Current Liabilities 702.0m) / Total Assets 4.63b |
| B: -0.03 (Retained Earnings -116.0m / Total Assets 4.63b) |
| C: -0.04 (EBIT TTM -193.0m / Avg Total Assets 4.42b) |
| D: 3.54 (Book Value of Equity 3.61b / Total Liabilities 1.02b) |
| Altman-Z'' = 4.26 = AA |
| DSRI: 1.03 (Receivables 655.0m/570.0m, Revenue 3.04b/2.71b) |
| GMI: 1.04 (GM 56.17% / 53.98%) |
| AQI: 0.91 (AQ_t 0.56 / AQ_t-1 0.61) |
| SGI: 1.12 (Revenue 3.04b / 2.71b) |
| TATA: -0.11 (NI -521.0m - CFO 3.00m) / TA 4.63b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 15.29 with a total of 827,478 shares traded. Over the past week, the price has changed by -1.92%, over one month by +3.94%, over three months by +9.84% and over the past year by -17.31%.
Current recommended Stop Loss: 13.20 (which is 13.7% or 2.5 ATR below the current price).
MiniMed , Common Stock has no consensus analysts rating.
P/S = 1.3612
P/B = 1.1682
Revenue TTM = 3.04b USD
EBIT TTM = -193.0m USD
EBITDA TTM = -40.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 145.0m USD (from shortTermDebt, last quarter)
Debt = 153.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.00m
Net Debt = -145.0m USD (calculated: Debt 153.0m - CCE 298.0m)
Enterprise Value = 4.08b USD (4.22b + Debt 153.0m - CCE 298.0m)
Interest Coverage Ratio = unknown (Ebit TTM -193.0m / Interest Expense TTM 0.0)
EV/FCF = -19.14x (Enterprise Value 4.08b / FCF TTM -213.0m)
FCF Yield = -5.22% (FCF TTM -213.0m / Enterprise Value 4.08b)
FCF Margin = -7.01% (FCF TTM -213.0m / Revenue TTM 3.04b)
Net Margin = -17.15% (Net Income TTM -521.0m / Revenue TTM 3.04b)
Gross Margin = 53.98% ((Revenue TTM 3.04b - Cost of Revenue TTM 1.40b) / Revenue TTM)
Gross Margin QoQ = 57.35% (prev 45.82%)
Tobins Q-Ratio = 0.88 (Enterprise Value 4.08b / Total Assets 4.63b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 153.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -152.5m (EBIT -193.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.92 (Total Current Assets 1.35b / Total Current Liabilities 702.0m)
Debt / Equity = 0.04 (Debt 153.0m / totalStockholderEquity, last quarter 3.61b)
Debt / EBITDA = 3.62 (negative EBITDA) (Net Debt -145.0m / EBITDA -40.0m)
Debt / FCF = 0.68 (negative FCF - burning cash) (Net Debt -145.0m / FCF TTM -213.0m)
Total Stockholder Equity = 3.54b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.80% (Net Income -521.0m / Total Assets 4.63b)
RoE = -14.73% (Net Income TTM -521.0m / Total Stockholder Equity 3.54b)
RoCE = -5.46% (EBIT -193.0m / Capital Employed (Equity 3.54b + L.T.Debt 0.0))
RoIC = -3.89% (negative operating profit) (NOPAT -152.5m / Invested Capital 3.92b)
WACC = 6.72% (E(4.22b)/V(4.38b) * Re(6.96%) + D(153.0m)/V(4.38b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -70.71 | Cagr: -5.99%
[DCF] Fair Price = unknown (Cash Flow -213.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.53 | Revenue CAGR: 12.09% | SUE: N/A | # QB: 0
EPS current Quarter (2026-07-31): EPS=0.11 | Chg30d=-13.49% | Revisions=-38% | Analysts=7
EPS next Quarter (2026-10-31): EPS=0.15 | Chg30d=-4.62% | Revisions=+0% | Analysts=7
EPS current Year (2027-04-30): EPS=0.66 | Chg30d=-0.78% | Revisions=+44% | GrowthEPS=+218.3% | GrowthRev=+15.8%
EPS next Year (2028-04-30): EPS=0.68 | Chg30d=-17.86% | Revisions=-22% | GrowthEPS=+3.4% | GrowthRev=+8.0%
[Analyst] Revisions Ratio: -4% (up=11, down=12)